Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2029

Conditions
Breast Cancer
Interventions
DRUG

Carboplatin and Paclitaxel

Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations

DRUG

Doxorubicin, cyclophosphamide

Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.

DRUG

Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide

"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."

Trial Locations (14)

1815 JD

Medisch Centrum Alkmaar, Alkmaar

1066 CX

NKI-AVL, Amsterdam

1090 HM

OLVG, Amsterdam

2625 AD

Reinier de Graaf Groep, Delft

7400 GC

Deventer Ziekenhuis, Deventer

Unknown

Albert Schweitzer ziekenhuis, Dordrecht

Ziekenhuis Gelderse Vallei, Ede

2000AK

Kennemer Gasthuis, Haarlem

6401 CX

Atrium Medisch Centrum Parkstad, Heerlen

2130 AT

Spaarne Ziekenhuis, Hoofddorp

2300 RC

LUMC, Leiden

3007 AC

Maasstad ziekenhuis, Rotterdam

2501 CK

Medisch Centrum Haaglanden, The Hague

8000 GK

Isala Klinieken, Zwolle

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER